文献速递皮肤肿瘤

氢氯噻嗪使用与梅克尔细胞癌及恶性皮肤附属器肿瘤风险:一项全国性病例对照研究

Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study.
PubMed 文献 · J Am Acad Dermatol · 2018-06-18

该全国性病例对照研究利用丹麦全国健康登记数据,纳入2004-2015年所有新发梅克尔细胞癌(MCC)或恶性皮肤附属器肿瘤(MAST)患者,并按风险集抽样匹配无癌人群对照。条件logistic回归显示,氢氯噻嗪高累积用量(≥50,000 mg)与MCC风险(OR 2.3,95%CI 1.1-4.8)及MAST风险(OR 3.6,95%CI 1.9-7.0)升高相关;最高用量(≥100,000 mg)时OR分别升至3.3(95%CI 1.3-8.3)和5.6(95%CI 2.4-13.3)。

要点

  • 氢氯噻嗪累积用量≥50,000 mg与MCC风险升高相关(OR 2.3,95%CI 1.1-4.8)。
  • 氢氯噻嗪累积用量≥50,000 mg与MAST风险升高相关(OR 3.6,95%CI 1.9-7.0)。
  • 最高用量(≥100,000 mg)时MCC和MAST的OR分别升至3.3和5.6。

核心结论

  • 氢氯噻嗪使用与梅克尔细胞癌(MCC)和恶性皮肤附属器肿瘤(MAST)风险升高相关。

研究设计与样本

  • 全国性病例对照研究,利用丹麦全国健康登记数据识别2004-2015年所有新发MCC或MAST患者,并按风险集抽样个体匹配无癌人群对照。
  • 采用条件logistic回归估计与氢氯噻嗪累积使用相关的OR和CI。

主要发现

  • 氢氯噻嗪高用量(≥50,000 mg)与MCC风险升高相关,调整OR为2.3(95%CI 1.1-4.8)。
  • 氢氯噻嗪高用量(≥50,000 mg)与MAST风险升高相关,调整OR为3.6(95%CI 1.9-7.0)。
  • 最高用量(≥100,000 mg)时,MCC的OR升至3.3(95%CI 1.3-8.3),MAST的OR升至5.6(95%CI 2.4-13.3)。
  • 分析具有与氢氯噻嗪相似适应症的药物时,未发现这些肿瘤风险升高,但使用呋塞米与MCC风险升高存在趋势(OR 1.9,95%CI 0.9-4.0)。

局限性

  • 无日光暴露数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hydrochlorothiazide use has been associated with markedly increased risk for squamous cell carcinoma. No previous studies have investigated the association between hydrochlorothiazide use and the risk for Merkel cell carcinoma (MCC) and malignant adnexal skin tumors (MAST). OBJECTIVE: To examine the association between hydrochlorothiazide use and the risk for MCC and MAST. METHODS: Using Danish nationwide health registries, we identified all patients with incident MCC or MAST during 2004-2015 and matched the cases individually to cancer-free population controls by risk set sampling. Using conditional logistic regression, we estimated the odds ratios (ORs) and confidence intervals (CIs) associated with cumulative use of hydrochlorothiazide. RESULTS: The adjusted ORs for MCC and MAST associated with high use (≥50,000 mg) of hydrochlorothiazide was 2.3 (95% CI 1.1-4.8) and 3.6 (95% CI 1.9-7.0), respectively, which increased to 3.3 (95% CI 1.3-8.3) and 5.6 (95% CI 2.4-13.3), respectively, with highest use (≥100,000 mg). We found no increased risk for these tumors in analyses of drugs with similar indications as hydrochlorothiazide, except there was a tendency toward an increased risk for MCC associated with the use of furosemide (OR 1.9, 95% CI 0.9-4.0). LIMITATIONS: No data on sun exposure was available. CONCLUSION: Hydrochlorothiazide use is associated with an increased risk for MCC and MAST.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Pedersen SA, Johannesdottir Schmidt SA, Hölmich LR, et al. Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study. J Am Acad Dermatol. 2018. PMID: 29913261. doi:10.1016/j.jaad.2018.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。